INTRODUCTION
Deferasiro x is an iron chelating agent indicated in the treatment of chronic iron overload in patients who are receiving long term blood transfusions for conditions such as beta-thalassemia and other chronic anemias 1 . Its chemical name is [4- [(3Z,5E)-3,5-bis(6-o xo -1-cyclohexa -2,4-dienylidene)-1,2,4-triazolidin -1-yl] benzoic acid 2 . Deferasiro x is a new tridentate oral iron chelator developed by computer remodeling recently approved by FDA for children above 2 years. It is the first oral medicat ion approved in the USA for this purpose 1 . Ferric iron has six coordination sites, which need to be chelated completely to prevent the generation of free radicals. Deferasiro x wo rks in treating iron toxicity by binding trivalent (ferric) iron (for which it has a strong affinity), forming a stable complex which is eliminated via the kidneys 1 . Few HPLC and LC methods for determination of Deferasiro x were reported in the literature review 5, 6, 7 and some reports mainly included the determination of Deferasiro x in b iological fluids 8, 9 . The aim of this work is to develop a rapid, economical and sensitive RP-HPLC method for identify ing these impurit ies at low level is very important. In order to develop a robustness method there is an immense need for developing a rapid, sensitive and validated analytical method for day -today analysis, in routine analysis in quality control laboratories of the drug and which can be even applicable for pharmaceutical dosage forms 4 . 
MATERIALS AND METHODS

Materials and reagents
Deferasiro x bulk drug (99.79% purity) and potential impurities Salicylic ac id (85.00% purity) & Salicylamide (99.38% purity) were provided by quality standard labs. Acetonitrile (HPLC grade) were obtained fro m Merck.
Instrumentation
Chro matographic separation was performed with Shimadzu LC-2010 high performance liquid chro matography equipped with UV variab le wavelength detector. Chro matograms and data were recorded by means of LC solutions software. A Mettler Toledo Analytical Balance (XP6), an Ultra Sonicator (Bandelin Sonorex EN-200US) was used in the study.
The proposed method was validated according to the International Conference on Harmonization (ICH) guidelines 3 .
System suitability
The system suitability was assessed by the duplicate analysis of the drug which was spiked by all impurit ies at a concentration of 0.1% with respect to the test concentration of 0.1 mg/ ml. The acceptance criteria were the resolution between salicylamide and salicylic acid should not be less than 1.5 and tailing factor for Deferasiro x peak should not be more than 1.5. The theoretical plate count of Deferasiro x should not be less than 2000.
Linearity (Cali brati on curve)
Level solutions
A series of solutions in 5 concentrations of 50 %, 80 %, 100 %, 120 % and 150 % were prepared using the standard stock solution (w.r.t 0.1 µg/ ml). The linearity of the method was demonstrated by above prepared level concentration 50 %, 80 %, 100 %, 120 % and 150 % of the target concentration of 0.1 µg/ ml. About 10.0 µl of each of the above prepared solutions was injected onto the chromatographic s ystem and measured. The average peak area response was calculated.
The acceptance criteria were that the system suitability criteria should be meet and % Relative standard deviation for area of impurities should not be more than 5.0. The % RSD for the peak area of deferasiro x in reference solution should not be more than 5.0. The regression coefficient for each impurity should not be less than 0.99 and % of Y-Intercept should be ± 5.0 14.
Determinati on of Li mit of Detecti on and Li mit of Quantitation
The limit of detection and limit of quantificat ion of the impurities were determined by calculating the signal-to-noise ratio (S/N, i.e., 3.3 for LOD and 10 for LOQ) using the following equations designated by International Conference on Harmonization (ICH) 3 .
Calcul ati on LOD = 3.3 × σ/S LOQ = 10 × σ/S Where σ = standard deviation
PRECIS ION
The precision was demonstration under three categories.
System Precision
Single individual preparation of Deferasiro x drug substance was prepared with target concentration of about 0.1 mg/ ml for system precision.
Procedure
Injected six replicate inject ions 10.0 µl of above preparation into the chromatographic system and recorded the chromatograms. The relative standard deviation of the replicate inject ions was calculated.
Method Precision
Six indiv idual preparations of Deferasiro x drug substance spiked with impurities were prepared for method Precision.
Procedure
Injected 10.0 µl of above preparations into the chromatographic system and recorded the chromatograms. Calculated the % relative standard deviations for the peak area of Deferasiro x in reference solution and for the peak area of each impurity.
Intermedi ate precision [Ruggedness]
Demonstration of ruggedness was conducted by different analysts, systems, columns and in different days under similar conditions at different times. Six individual preparations of Deferasiro x drug substance spiked with impurities were prepared and each was analyzed.
The acceptance criteria for system, method and intermediate precision were that the system suitability criteria should be meet and the % Relative standard deviation for the peak area of Deferasiro x in refe rence solution from the six rep licate injections should be not more than 5.0 %. The % Relative standard deviation for the peak area of each impurity should not be more than 5.0 and for Deferasiro x should not be more than 2.0 %. 
Solution stability
The validity of the solutions was demonstrated for a period of 48 hrs by injecting the same solution at periodic intervals into the chromatographic system and the chromatograms were recorded.
Procedure
About 10 µl o f the standard solution was injected at 0 hr, 24 th hr and 48 th hr into the chromatographic system and recorded the peak areas in the chromatograms.
Calcul ati ons
Observed the areas of the peaks of Deferasiro x injected at the mentioned time intervals and the relative standard deviation of the injections was calculated.
The acceptance criteria were that the system suitability should pass as per the test method at variable conditions and % RSD for the peak area of Deferasiro x should not be more than 2.0.
Specificity
The specificity of the method was demonstrated by interference check by injecting the diluent blank, Deferasiro x and impurities solutions to determine whether any peaks in the diluent and impurities solutions are co-eluting with Deferasiro x peaks.
RES ULTS AND DISCUSS ION
Method development and opti mization
Deferasiro x is soluble in methanol and acetonitrile 2 . The drug can be separated on a Inertsil ODS-3V colu mn in reverse phase HPLC. The optimization of the method development was done by isocratic elution.
The peak shapes and symmetry of Deferasiro x and impurit ies were good with above isocratic elution and peaks were resolved with greater than 1.5 resolution at a isocratic flow rate. The method developed was unique in determining the impurities even at low levels than that of specifications. The developed method was successfully applied to estimate the amount of Deferasiro x. 
Method Vali dation System Suitability
Resolution was not less than 1.5, number of theoretical p lates was not less than 2000, and percentage relative standard deviation (%RSD) for Peak Area was not more than 2.0 % for Deferasiro x peaks. The %RSD o f peak area for the drug is within 2% indicating the suitability of the system (Table 1 ). The efficiency of the colu mn as expressed by number of theoretical plates and the tailing factor was 0.90. 
Acceptance criteria
Resolution was not less than 1.5, number of theoretical plates was not less than 2000, and percentage relative standard deviation (%RSD) for Peak Area was not more than 2.0 % for Deferasiro x peaks as per ICH guidelines 3 .
Linearity
The calibration curve constructed was evaluated by its correlation coefficient. The peak area of the impurities of the drug was linear in the range of 0.05 µg/ ml to 0.15 µg/ml. 
Acceptance Criteria
Coefficient of correlation should be not less than 0.999
LOD and LOQ
The limit of detection and limit of quantification of the impurities is determined by taking the slope and intercept values from linearity studies. Limit of detection is calculated by using the formula LOD = 3.3 X σ/S and limit of detection is calculated by using the formula LOQ = 10 X σ/S. Limit of detection (LOD) for salicylamide was found to be 0.0060 µg/ ml and Limit of quantitation (LOQ) for salicy lamide was found to be 0.0182 µg/ml and LOD for salicylic acid was found to be 0.0028 µg/ ml and LOQ for salicylic acid was found to be 0.0087 µg/ ml.
Precision
The precision was demonstration under three categories. 
Acceptance criteria
The % RSD for the area of five standard injections of Deferasiro x results should not be more than 2%. 
The % RSD for the area six standard injections of Deferasiro x spiked with impurities results should not be more than 2%. 
The % RSD for the area six standard injections of Deferasiro x spiked with impurit ies results should not be more than 2%.
Solution stability
The validity of the solutions was demonstrated for a period of 48 hrs by injecting the same solution at 0 and 48 hrs intervals into the chromatographic system and the chromatograms were recorded. 
Calcul ati ons
Specificity
The specificity of the method was demonstrated by interference check by injecting the diluent blank, Deferasiro x and impurit ies solutions to determine whether any peaks in the diluent and impurities solutions are coeluting with Deferasiro x peaks. 
Acceptance criteria
Resolution was not less than 1.5, number of theoretical plates was not less than 2000, and percentage relative standard deviation (%RSD) for Peak Area was not more than 2.0 % for Deferasiro x peaks.
ROB US TNESS
The Robustness studies were performed for the standard solutions and were presented in respectively (Table 9 , 10 and 11). The values are within the limit wh ich showed that the developed method is robust. 
CONCLUS ION
A simp le and isocratic reverse phase high performance liquid chromatography (RP-HPLC) method was developed and validated for determination of impurit ies in Deferasiro x. The method was validated as per International Conference on Harmonizat ion (ICHQ2 (R1)) guidelines for system suitability, precision, linearity, specificity, solution stability, robustness and ruggedness, limit of detection and limit of quantitation. Deferasiro x was analyzed by using Inertsil ODS-3V (150 X 4.6 mm; 5 µm) at 35ºC temperature with isocratic elution. The analysis was performed at a wavelength of 245 n m using UV-Vis detector. Efficient UV detection at 245 n m enabled determination of Deferasiro x without any interference of impurities Salicylic acid and Salicylamide. The retention time (RT) for Deferasiro x was around 8.7 min.
The impurit ies are potential impurities. Thus identifying these impurit ies at low level is crucial. The calibration curves were linear over a concentration range fro m 0.05 µg/ml to 0.15 µg/ ml. Limit of detection (LOD) for salicy lamide was found to be 0.0060 µg/ ml and Limit of quantitation (LOQ) for salicylamide was found to be 0.0182 µg/ ml and LOD for salicylic acid was found to be 0.0028 µg/ ml and LOQ for salicylic acid was found to be 0.0087 µg/ ml. The method developed was unique in determining the impurit ies even at low levels than that of specifications. The developed method was successfully applied to estimate the amount of Deferasiro x. The proposed RP-HPLC method is precise, sensitive, accurate, specific and efficient and can be used in routine analysis in quality control laboratories.
